Compare Amgen, Inc. (AMGN) vs TORM plc (TRMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs TORM plc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while TORM plc trades at $29.65 (market cap $2.94B). The key difference: Amgen, Inc. is far larger — about 66.7× TORM plc's market cap, and TORM plc pays the higher dividend (9.5%). Which is the better fit depends on your goals.
| AMGN | TRMD | |
|---|---|---|
Market Cap | $196.12B | $2.94B |
Sector | Health | Technology |
52-Week High | $388.16 | $34.87 |
52-Week Low | $271.18 | $17.46 |
Enterprise Value | $241.41B | $3.82B |
Dividend Yield | 2.77% | 9.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
TRMD trades at $29.48, up 5.06% today, with technical indicators showing a neutral bias and support near $28. The stock exhibits strong profitability with a 24.41% net margin and attractive valuation at a P/E of 8.65. Recent Q1 2026 earnings missed estimates but full-year guidance was raised, reflecting robust tanker market conditions. A $0.70 dividend for H1 2026 underscores shareholder returns.
Outlook remains positive given firm freight rates and strategic execution, though volatility from geopolitical factors and earnings misses pose risks. Analyst consensus is unanimously bullish, supporting upside potential if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
